Letter to Stockholders |
Business Events |
Financial Highlights
Pipeline Profile |
Marketed Product News |
Business Partner News
- Promoted William D. Young to chief operating officer.
- Promoted Louis J. Lavigne, Jr., to executive vice president.
- Promoted Joffre B. Baker, Ph.D., to vice president-Research Discovery and Paula Jardieu, Ph.D., to vice president-Pharmacological Sciences.
- Received regulatory clearance to market Nutropin AQ™ [somatropin (rDNA origin) injection] liquid formulation growth hormone for the treatment of short stature from Turner syndrome. Nutropin AQ now has regulatory clearance for the same indications as Nutropin® [somatropin (rDNA origin) for injection] growth hormone.
- Genentech and its partners IDEC Pharmaceuticals and Roche have submitted worldwide regulatory filings seeking marketing clearance for IDEC's C2B8 antibody in the treatment of relapsed low-grade non-Hodgkin's B-cell lymphoma.
- Entered into an agreement with Roche under which Genentech will promote Roche's Roferon®-A (Interferon alfa-2a, recombinant) in the United States for its approved oncology indications.
- Obtained results from the GUSTO III study, announced at the American College of Cardiology annual meeting, which demonstrated that a new thrombolytic agent, Retavase™ (Reteplase), does not save more lives than Activase in the treatment of acute myocardial infarction.
- Genentech's partner Scios Inc. discontinued development of Auriculin® (anaritide) after an interim analysis of data from an ongoing Phase III study in oliguric acute renal failure suggested a low probability that a positive outcome could be obtained with respect to its primary clinical endpoint, dialysis-free survival.
- Completed enrollment in pivotal Phase III clinical trials of the anti-HER2 antibody for the treatment of breast cancer.
- Completed enrollment in one of two international Phase II trials for the second-generation thrombolytic, TNK.
|
